Presenting new, potentially groundbreaking data at a prestigious conference can significantly impact investor perception, especially in the biotechnology sector where advancements in treatments can lead to substantial market value changes. Given the focus on Foralumab, a promising treatment in neurology, this presentation could be seen as a positive development for Tiziana Life Sciences, potentially leading to increased investor interest and a short-term rise in stock price.